4, 5 After 72 hours of incubation, concentrations of 0.5, 1.0, and 2.0 Temozolomide μM AG1517 combined with 2.5, 5.0, and 10.0 μM AG879, respectively, produced a synergistic inhibitory effect (CI < 1.0) on BDEneu cell growth in vitro over that produced by either ErbB TK inhibitor alone (Fig. 3A). Similarly, 15 μM AG1517 in combination with 7.5 μM AG879 also showed a synergistic growth inhibition of cultured C611B cells compared with that produced by 15 μM AG1517 or 7.5 μM AG879 alone

(Fig. 3B). To establish a mechanism for this synergistic cell growth inhibition, we used quantitative western blotting to examine the effects of AG1517 and AG879 alone and in combination on phosphorylation states of key proteins in the

ErbB1 and ErbB2 signaling pathways. Our results (Fig. 3C,D) demonstrate that after 16 hours of incubation, the AG1517/AG879 combination significantly enhances the inhibition of ErbB1 and ErbB2 signaling in both cultured BDEneu and C611B cells over that produced by either ErbB TK inhibitor alone, as reflected by marked decreases in the phosphorylated levels of ErbB1, ErbB2, serine/threonine kinase Akt/protein kinase B (Akt), and p42/44 MAPK in the combination-treated cells compared Selleckchem PD0332991 with phosphorylated levels of corresponding proteins in the DMSO-treated control and single-agent–treated cholangiocarcinoma cell cultures. The AG1517/AG879 combination treatment is also associated with a suppression of cyclin D1 protein expression and with activation of caspase-3 (Supporting Fig. 2). Although we expected partial decreases in the phosphorylated levels of ErbB signaling proteins in the cultures treated with AG1517 or AG879 alone, we also noted that single-agent treatment with the ErbB2 RTK, AG879, resulted in significant increases in the phosphorylated levels of both ErbB1 and p42/44

MAPK in both the BDEneu and C611B cholangiocarcinoma cell lines over DMSO-treated control values (Fig. 3C,D). AG879 treatment also increased ErbB1 Flucloronide autophosphorylation at Tyr1173 in both cultured HuCCT1 cells and TFK1 human cholangiocarcinoma cells (Fig. 3E,F). In addition, treatment with another ErbB2 TK inhibitor, tryphostin AG825, produced elevated levels of phosphorylated ErbB1 and p42/44 MAPK in cultured BDEneu cells (data not shown). The dual ErbB1/ErbB2 TK inhibitor lapatinib was found after 72 hours of incubation to be an even more potent inhibitor of cell growth than either tryphostin AG1517 or AG879, alone or in combination (Fig. 4A compared with Fig. 3A,B), when tested in vitro against the cholangiocarcinoma cell lines. Lapatinib at the 8.